Navigation Links
Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
Date:12/5/2007

THE WOODLANDS, Texas, Dec. 5 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that dosing has commenced in a Phase 2a clinical trial with LX6171, an oral drug candidate for the treatment of cognitive impairment associated with disorders such as Alzheimer's disease, schizophrenia, and vascular dementia. The initial stage of the trial will assess the bioavailability of a new oral-suspension formulation in healthy elderly subjects with a second stage evaluating safety, tolerability and cognitive effects in elderly subjects with age-associated memory impairment (AAMI).

"AAMI is an emerging area of clinical research and offers an expedient population for obtaining proof-of-concept with a drug candidate, like LX6171, that has a broad range of potential applications in the area of cognitive disorders," said Philip M. Brown, M.D., J.D., vice president of clinical development at Lexicon. "Following the strength of the Phase 1 data indicating LX6171 is generally well tolerated, we have adopted a two-stage strategy for Phase 2a in order to transition to our new oral suspension formulation and to assess for improvements in a variety of cognitive dimensions as we enter the elderly population."

Phase 2 Study Design

The initial stage of the trial will assess the bioavailability of a single-dose oral suspension in 16 healthy elderly subjects. The second stage will be a randomized, double-blind, placebo-controlled evaluation of safety, tolerability, and cognitive effects in approximately 120 subjects over four weeks. This stage is anticipated to include three groups of 40 subjects each, exploring two dose levels with a placebo control. Exact dose levels for the second stage wi
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
9. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
10. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 1, 2014  ResMed (NYSE: RMD ), a ... company to design complete sleep apnea solutions specifically for women, ... importance of a good night,s sleep. The ... that feeling tired is just part of living a busy ... a critical pillar of health, essential to not only living ...
(Date:10/1/2014)... 1, 2014 Trovagene, Inc., (NASDAQ:  TROV) ... that Eli Diamond , MD, Assistant Attending ... presented clinical data from an ongoing study demonstrating ... for the determination of oncogene mutational status in ... results were presented to both treating physicians and ...
(Date:10/1/2014)... 2014  Express Scripts (NASDAQ: ESRX ) ... Scripts Medicare ® Prescription Drug Plans (PDP) will ... WAG ) (NASDAQ: WAG ), ... support  for their Medicare dollars. Medicare beneficiaries ... or Choice plans for 2015 can ...
Breaking Medicine Technology:ResMed Launches Initiative to Help Women Get Better Sleep 2ResMed Launches Initiative to Help Women Get Better Sleep 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 3Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 4
... NEW YORK, Feb. 6, 2012 ... market research report is available ... Commercializing Angiogenesis Affecting ... Route to Consider Your Options ...
... Reportlinker.com announces that a new market research ... , World Market for Anti-Infectives (Antifungals, ... http://www.reportlinker.com/p0769020/World-Market-for-Anti-Infectives-Antifungals-Antibacterials-and-Antivirals- .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication ... World Market for Anti-Infectives - focuses ...
Cached Medicine Technology:Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 2Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 3Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 4Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 5Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 6Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 7Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 8Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 9Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 10Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 11Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 12Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 13Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 14Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 15Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 16Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 17Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 18Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 19World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 2World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 3World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 4World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 5World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 6World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 7World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 8World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 9
(Date:10/1/2014)... research suggests the adage that encourages people to keep ... when it comes to exercise. When walking, staying focused ... to it appear shorter and help people walk there ... this technique to walking while looking around the environment ... of exercise. , "People are less interested in exercise ...
(Date:10/1/2014)... Insuranceragents.info has released a new blog ... plan for vulnerable family members. , Life insurance plans ... in the family should always carry a life insurance ... the rest of the family. , Clients can ... more from temporary coverage or from a permanent policy. ...
(Date:10/1/2014)... First Warning Systems, a pioneer in ... throughout the body, announced the company is changing its ... company’s breadth of upcoming product releases. The initial focus ... , “Our initial focus will be an ‘Internet of ... circadian cellular changes over time,” said Rob Royea, president ...
(Date:10/1/2014)... Farmington Company today announced it ... and visual identity helping brokers, consultants and companies ... to create greater benefit communication synergies. They unveiled ... empowering customers to better leverage Farmington Company’s industry-tested ... of the rebrand is the refreshed tagline: For ...
(Date:10/1/2014)... California (PRWEB) October 01, 2014 Beverly ... Dr. Kathleen Mojas is celebrating 20 years of private ... assisted hundreds of people to achieve greater joy and ... important list of warning signs and suggestions for anyone ... Dr. Mojas explains: “Believe it or not, it’s ...
Breaking Medicine News(10 mins):Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3
... patients with cirrhosis have significant functional disability, require twice ... on the health care system, according to U-M research ... increase in obesity and aging of those with hepatitis ... climb among older Americans.. Cirrhosis is a ...
... TUESDAY, Jan. 10 (HealthDay News) -- Asian-Americans are more ... attack than whites, new research reveals, although this disparity ... quality improvement program. In the study, doctors examined ... patient was prescribed aspirin or ACE inhibitors (heart drugs) ...
... shows that older Americans with cirrhosis have significantly worse ... without this potentially deadly disease. In fact, findings now ... the American Association for the Study of Liver Diseases, ... amount of informal caregiving and contribute added strain on ...
... HealthDay Reporter , TUESDAY, Jan. 10 (HealthDay ... early clinical trial of the drug Nexavar (sorafenib) in ... in better news, an experimental drug known as ganetespib ... The results of both studies were to be presented ...
... 10, 2012. Kessler Foundation and the University of ... collaborate on clinical research projects applying virtual reality ... goal, according to USC,s Albert Rizzo, PhD of ... to conduct research to develop the evidence base ...
... Reporter , MONDAY, Jan. 9 (HealthDay News) -- For years, people ... of dying from a heart attack, stroke or cancer even if ... into question. Low-dose daily aspirin therapy does not reduce ... new study in the Jan. 9 online edition of the ...
Cached Medicine News:Health News:High rates of disability and health care use found in older Americans with cirrhosis 2Health News:Asian-Americans More Apt to Die in Hospital After Heart Attacks 2Health News:High rates of disability and health care use for older americans with cirrhosis 2Health News:Mixed News on Tough-to-Treat Lung Cancer 2Health News:Mixed News on Tough-to-Treat Lung Cancer 3Health News:Kessler Foundation and USC collaborate on clinical virtual reality for disability research 2Health News:Low-Dose Aspirin to Prevent First Heart Attack or Stroke? Not So Fast 2Health News:Low-Dose Aspirin to Prevent First Heart Attack or Stroke? Not So Fast 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: